Skip to content
10-K

Annual Report

CTI BIOPHARMA CORP

0000891293-22-000010

← back to feed
Filed
Mar 31, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 17, 2022 99.92M sh
Capex FY 2021 · Dec 31, 2021 $0
Capex FY 2021 · Dec 31, 2020 $17K
Shares Diluted FY 2021 · Dec 31, 2020 71.14M sh
Operating Cash Flow FY 2021 · Dec 31, 2020 −$42.21M
Short Term Debt FY 2021 · Dec 31, 2020 $4.46M
Short Term Investments FY 2021 · Dec 31, 2020 $12.06M
Cash And Equivalents FY 2021 · Dec 31, 2020 $40.39M
Current Liabilities FY 2021 · Dec 31, 2020 $17.04M
Total Liabilities FY 2021 · Dec 31, 2020 $18.21M
Current Assets FY 2021 · Dec 31, 2020 $54.33M
Total Assets FY 2021 · Dec 31, 2020 $58.24M
Eps Diluted FY 2021 · Dec 31, 2020 −$0.74
Eps Basic FY 2021 · Dec 31, 2020 −$0.74
Sga Expense FY 2021 · Dec 31, 2020 $17.63M
Net Income FY 2021 · Dec 31, 2020 −$52.45M
Operating Income FY 2021 · Dec 31, 2020 −$47.77M